Two new treatment options for infections due to drug-resistant gram-positive cocci.

Vancomycin use in a brazilian teaching hospital: comparison with the Hospital Infection Controlpractices Advisory Committee Guidelines (HICPAC)

“…Studies suggest that, even in the absence of restriction policies, vancomycin use is not more than 40% of the guidelines recommendations [36,38,39,42]. Other studies have shown that antibiotic control measures can reduce total vancomycin use [18,39].…”

“…Inadequate therapy is closely correlated with adverse patient outcomes, including increased rates of hospital mortality [35,38,39].…”

Vancomycin use in a hospital with high prevalence of Methicillin-Resistant Staphylococcus aureus: comparison with Hospital Infection Control Practices Advisory Committe Guidelines (HICPAC)

“…Daily prices of intravenous therapy of linezolid and quinupristin-dalfopristin are substantially higher than vancomycin, achieving $140 and $320, respectively [36].…”

A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients

“…Acquisition costs for both linezolid and Q/D are substantially higher than acquisition costs for vancomycin. Per day of intravenous therapy, the cost of linezolid and Q/D are approximately $140 and $320, respectively [72]. Oral linezolid is slightly less expensive (approximately $106) than the intravenous formulation per day of therapy.…”